News
08-27-2010
Nikolay Merkin, Chemrar Ventures: ‘We will create innovative treatment for $10 mln’
ChemRar Hi-Tech Center is one of the most active players on the market of highly innovative pharmaceuticals. Center’s portfolio boasts dozens of projects including cancer, HIV and hepatitis C medications, as well as treatments for CIS diseases. Nikolay Merkin, CEO of ChemRar Ventures, told UNOVA about ChemRar Hi-Tech Center, its cooperation with Rosnano, Russian Venture Company and peculiarities of the pharmaceutical market.
07-15-2010
Andrei Ivachtchenko, Chairman of the Board of Directors of High-Tech Center ChemRar, discusses successful models of bringing innovative Pharma programs to Russia
07-09-2010
Rusnano invests in development of portfolio of innovative pharmaceuticals
with ChemRar
ChemRar Hi Tech Center announced partnership with RUSNANO that will help develop and commercialize Russian innovative pharmaceuticals. RUSNANO has approved investments of up to $40 million in equity of the project company. Project revenue in 2015 is forecasted at $36 million and during the period 2017–2019, $85 million to $150 million.
07-06-2010
ChemRar and Rusnano Back Biocluster for Innovative Drugs in Russia
Russia's nascent commercial drug industry could get a shot in the arm from a
US$163-million project announced yesterday. But the project - which is
partly bankrolled by a state-owned non-profit corporation - faces a
challenging future, despite government backing.
06-08-2010
ChemRar and R-Pharm announced Joint Venture for production of drugs’ active substances in Yaroslavl, Russia
Center for High Technology "ChemRar" and CJSC "R-Farm" are to establish a joint venture for production of drugs’ active substances in Yaroslavl.
06-08-2010
Torrey Pines will present at BIO Deutschdland European Business Development Conference
04-12-2010
TPI and Afraxis speaking about VC View on Chemistry Outsourcing
03-28-2010
TPI Investment Model Featured in Dow Jones VentureWire
03-16-2010
Torrey Pines Investment will attend C21 BioVentures™ on May 25-27, 2010
03-03-2010
Torrey Pines Investment and Avalon Ventures on the AFraxis deal at San Diego Venture Group meeting
The article "AFraxis CEO Outlines Biotech's Success With Ultra-Lean Pre-Clinical R&D in Russia" by Bruce V. Bigelow discusses the AFraxis deal between Torrey Pines Investment and Avalon Ventures
03-12-2010
Torrey Pines and ChemRar investment in early development assets is gaining momentum in 2010
The article "Torrey Pines To Raise Additional USD 150m To Invest In Clinical/Preclinical Assets" by Mintoi Chessa-Florea analyzes the latest Torrey Pines and ChemRar investment in early development assets
03-16-2010
Torrey Pines Investment will be participating in 7th Annual Life Sciences Investor & Entrepreneur Roundtables
12-11-2009
Torrey Pines Investment will attend OneMedForum 2010 in San Francisco
11-20-2009
Torrey Pines Investment will participate in J.P.Morgan 28th Annual Healthcare Conference
11-04-2009
Neuronascent Announces Collaboration with ChemRar for Characterization of Developmental Pathway Inhibitors Using Neuronascent’s Neurogenesis Platform
Clarksville, MD [11.04.09] – Neuronascent, Inc., a privately-held biotechnology company developing novel, neurogenic small-molecule drugs for the treatment of depression, Down syndrome, Alzheimer’s, Parkinson’s...
10-26-2009
Roche and Viriom sign license agreement for innovative drugs against HIV
In a first-of-its kind deal, Roche recently licensed a handful of pre-clinical HIV assets to Russian biotech Viriom, a start-up created specifically to develop and commercialize the compounds in Russia, Ukraine, Belarus and Kazakhstan.
10-19-2009
Viriom Selects ChemDiv to Develop HIV Program
ChemDiv has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) has been chosen by Viriom Ltd. as a service partner in developing innovative HIV compounds.
09-19-2009
ChemDiv and iDialog nominate novel inhibitor of Hepatitis C for clinical development
ChemDiv Inc. of San Diego, and iDialog (Intellektualniy Dialog) of Yaroslavl, Russia, announced today the successful completion of a pre-clinical development...
09-15-2009
ChemDiv and Avineuro Pharmaceuticals Announce Successful Milestones Reached
ChemDiv Inc. of San Diego CA and Avineuro Pharmaceuticals Inc. of San Diego CA announced successful milestones reached under ongoing research and development collaboration in area of neurodegenerative and psychiatric disorders.
